Pulses are racing!

Posted:
15
September 2004

Excitement is mounting at Richmond Pharmacology as we approach the QTc workshop to be held on 29th September 2004 at St George's Hospital Medical School. The workshop has received much interest and is expected to be a huge success.Richmond Pharmacology has invited main representatives from the top pharmaceutical companies to attend a workshop where world-leading experts in cardiology from St George's Hospital Medical School and also the Medicines and Healthcare Products Regulatory Authority (MHRA) will speak on a range of QTc topics.Studies focussing on the QT interval have become of increased importance recently. A number of drugs have been withdrawn from the market as a result of their capacity to cause potentially fatal arrhythmias associated with the prolongation of the QT interval. Factors influencing the QT interval, regulatory aspects of drug induced QT interval prolongation, correcting or controlling the QT interval, and the definitive QT study will all be discussed, among other topics, at the workshop hosted by Richmond Pharmacology.To find more information on Richmond Pharmacology's QTc capabilities, or for further information on the QTc workshop, follow the link to our QTc studies page.It is not too late to register, please see the workshop page for further information. The QTc Studies page provides up to date information on the services offered by RPL in this area of expertise.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more